Immunosuppressive and cytotoxic therapy: Pharmacology, toxicities, and monitoring

Seminars in Respiratory and Critical Care Medicine

Volumn 32, Issue 3, 2011, Pages 346-370

  Wang, Tisha ^a   Weigt, S Sam ^a   Belperio, John A ^a   Lynch, Joseph P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

anti neutrophil cytoplasmic antibodies; azathioprine; cyclophosphamide; immunosuppressive medications; intravenous immunoglobulin G; methotrexate; mycophenolate mofetil; rituximab; tumor necrosis factor inhibitors; Vasculitis

Indexed keywords

ADALIMUMAB; ALLOPURINOL; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOLIC ACID; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LORAZEPAM; MERCAPTOPURINE; MESNA; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABDOMINAL PAIN; ABORTION; ACUTE KIDNEY FAILURE; ACUTE LEUKEMIA; ALOPECIA; AMENORRHEA; ANAPHYLAXIS; ANCA ASSOCIATED VASCULITIS; ANEMIA; ANGIONEUROTIC EDEMA; ANOREXIA; ARTHRALGIA; ARTICLE; ASPERGILLOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; AZOOSPERMIA; B LYMPHOCYTE; BACKACHE; BEHCET DISEASE; BLADDER CANCER; BLOOD CELL COUNT; BLOOD PRESSURE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; BRONCHOSPASM; CANCER CHEMOTHERAPY; CHILL; CHURG STRAUSS SYNDROME; COCCIDIOIDOMYCOSIS; COGNITIVE DEFECT; COLON CANCER; CORTICOSTEROID THERAPY; COUGHING; CRYPTOCOCCOSIS; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED CANCER; DRUG INDUCED HEADACHE; DRUG PROTEIN BINDING; DYSPHORIA; DYSPNEA; ENCEPHALOMALACIA; ENTERITIS; FATIGUE; FATTY LIVER; FETUS MALFORMATION; FIBROSING ALVEOLITIS; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HEART INFARCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HEPATITIS B; HERPES SIMPLEX; HERPES ZOSTER; HISTOPLASMOSIS; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFLAMMATORY DISEASE; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY FAILURE; LEUKEMIA; LEUKOPENIA; LISTERIOSIS; LIVER FIBROSIS; LIVER TOXICITY; LUNG CANCER; LUNG FIBROSIS; LUNG HEMORRHAGE; LUNG INFILTRATE; LUNG TOXICITY; LUPUS LIKE SYNDROME; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; LYMPHOMA; MEGALOBLASTIC ANEMIA; MUCOCUTANEOUS LYMPH NODE SYNDROME; MUCOSA INFLAMMATION; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; MYALGIA; MYCOBACTERIOSIS; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NOCARDIOSIS; OBSTRUCTIVE JAUNDICE; OLIGOSPERMIA; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; OVARY INSUFFICIENCY; PANCREATITIS; PANCYTOPENIA; PATIENT MONITORING; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROSTATE CANCER; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PURE RED CELL ANEMIA; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SARCOIDOSIS; SEIZURE; SEPSIS; SIDE EFFECT; SKIN INFECTION; SKIN TOXICITY; SNEEZING; SOFT TISSUE INFECTION; SQUAMOUS CELL CARCINOMA; STEVENS JOHNSON SYNDROME; STOMATITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TERATOGENESIS; TERATOGENICITY; THROAT IRRITATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; THYROID CANCER; TREATMENT DURATION; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; URTICARIA; UTERUS CANCER; VIRUS INFECTION; VIRUS REACTIVATION; VOMITING; WEGENER GRANULOMATOSIS;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; AZATHIOPRINE; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; MYCOPHENOLIC ACID; TIME FACTORS;

EID: 79959276498     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0031-1279831     Document Type: Article

References (304)

1. Frankel S K., Jayne D. The pulmonary vasculitides. Clin Chest Med 2010 31 3 519-536
2. Lynch J P. III, White E, Tazelaar H, Langford C A. Wegener's granulomatosis: evolving concepts in treatment. Semin Respir Crit Care Med 2004 25 5 491-521 (Pubitemid 39518246)
3. Hoffman G S., Kerr G S., Leavitt R Y. et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992 116 6 488-498
4. Jayne D, Rasmussen N, Andrassy K et al, European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003 349 1 36-44 (Pubitemid 36765101)
5. Reinhold-Keller E, Fink C O., Herlyn K, Gross W L., De Groot K. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 2002 47 3 326-332 (Pubitemid 34627702)
6. Pagnoux C, Mahr A, Hamidou M A. et al, French Vasculitis Study Group. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008 359 26 2790-2803
7. Sneller M C., Hoffman G S., Talar-Williams C, Kerr G S., Hallahan C W., Fauci A S. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995 38 5 608-613
8. Villa-Forte A, Clark T M., Gomes M et al. Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience. Medicine (Baltimore) 2007 86 5 269-277 (Pubitemid 47415005)
9. Jayne D. Leflunomide versus methotrexate in Wegener's granulomatosis. Rheumatology (Oxford) 2007 46 7 1047-1048 (Pubitemid 47050600)
10. McDonough A K., Curtis J R., Saag K G. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 2008 20 2 131-137 (Pubitemid 351339883)
11. Stone J H., Merkel P A., Spiera R et al, RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010 363 3 221-232
12. Jones R B., Tervaert J W., Hauser T et al, European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010 363 3 211-220
13. Klemmer P J., Chalermskulrat W, Reif M S., Hogan S L., Henke D C., Falk R J. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 2003 42 6 1149-1153 (Pubitemid 37486757)
14. Wang C C., Shiang J C., Tsai M K. et al. Prompt plasmapheresis successfully rescue pulmonary-renal syndrome caused by ANCA-negative microscopic polyangiitis. Clin Rheumatol 2009 28 12 1457-1460
15. Stone J H., Uhlfelder M L., Hellmann D B., Crook S, Bedocs N M., Hoffman G S. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 2001 44 5 1149-1154 (Pubitemid 32433622)
16. Josselin L, Mahr A, Cohen P et al. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. Ann Rheum Dis 2008 67 9 1343-1346
17. Martinez V, Cohen P, Pagnoux C et al, French Vasculitis Study Group. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum 2008 58 1 308-317
18. Metzler C, Miehle N, Manger K et al, German Network of Rheumatic Diseases. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 2007 46 7 1087-1091 (Pubitemid 47050609)
19. Metzler C, Fink C, Lamprecht P, Gross W L., Reinhold-Keller E. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxford) 2004 43 3 315-320 (Pubitemid 38313180)
20. Ghez D, Westeel P F., Henry I, Pruna A, Fournier A, Lassoued K. Control of a relapse and induction of long-term remission of Wegener's granulomatosis by cyclosporine. Am J Kidney Dis 2002 40 2 E6
21. Koening C L., Hernndez-Rodrguez J, Molloy E S., Clark T M., Hoffman G S. Limited utility of rapamycin in severe, refractory Wegener's granulomatosis. J Rheumatol 2009 36 1 116-119
22. Schmitt W H., Hagen E C., Neumann I, Nowack R, Flores-Surez L F., van der Woude F J., European Vasculitis Study Group. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 2004 65 4 1440-1448 (Pubitemid 38406986)
23. Papo T, Le Thi Huong D, Wiederkehr J L. et al. Etoposide in Wegener's granulomatosis. Rheumatology (Oxford) 1999 38 5 473-475
24. Flossmann O, Jayne D R. Long-term treatment of relapsing Wegener's granulomatosis with 15-deoxyspergualin. Rheumatology (Oxford) 2010 49 3 556-562
25. Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis 2008 67 9 1322-1327
26. Lockwood C M., Thiru S, Stewart S et al. Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. QJM 1996 89 12 903-912 (Pubitemid 27016320)
27. Seror R, Pagnoux C, Ruivard M et al, French Vasculitis Study Group. Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial. Ann Rheum Dis 2010 69 12 2125-2130
28. Meyer K C., Decker C, Baughman R. Toxicity and monitoring of immunosuppressive therapy used in systemic autoimmune diseases. Clin Chest Med 2010 31 3 565-588
29. Marder W, McCune W J. Advances in immunosuppressive therapy. Semin Respir Crit Care Med 2007 28 4 398-417 (Pubitemid 350194723)
30. Lynch J P. III, McCune W J. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med 1997 155 2 395-420 (Pubitemid 27085778)
31. de Groot K, Harper L, Jayne D R. et al, EUVAS (European Vasculitis Study Group). Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009 150 10 670-680
32. Levitt M, Warr D, Yelle L et al. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. N Engl J Med 1993 328 15 1081-1084 (Pubitemid 23097797)
33. Hoffman G S., Leavitt R Y., Fleisher T A., Minor J R., Fauci A S. Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med 1990 89 4 403-410 (Pubitemid 20365386)
34. Reinhold-Keller E, Kekow J, Schnabel A et al. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum 1994 37 6 919-924 (Pubitemid 24184546)
35. Guillevin L, Cordier J F., Lhote F et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997 40 12 2187-2198 (Pubitemid 28016415)
36. de Groot K, Adu D, Savage C O., EUVAS (European vasculitis study group). The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001 16 10 2018-2027 (Pubitemid 32970564)
37. Wolverton S E., Remlinger K. Suggested guidelines for patient monitoring: hepatic and hematologic toxicity attributable to systemic dermatologic drugs. Dermatol Clin 2007 25 2 195-205, viii (Pubitemid 46553775)
38. Pedersen-Bjergaard J, ErsbØll J, SØrensen H M. et al. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas: comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann Intern Med 1985 103 2 195-200 (Pubitemid 15000568)
39. Faurschou M, Sorensen I J., Mellemkjaer L et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008 35 1 100-105
40. Campora E, Giudici S, Merlini L, Rubagotti A, Rosso R. Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide- doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses. Am J Clin Oncol 1994 17 6 522-526 (Pubitemid 24379359)
41. Du L T., Rigaud D, Papo T, Godeau P. Cyclophosphamide-induced hepatitis in Wegener's granulomatosis. Mayo Clin Proc 1994 69 9 912-913
42. Snyder L S., Heigh R I., Anderson M L. Cyclophosphamide-induced hepatotoxicity in a patient with Wegener's granulomatosis. Mayo Clin Proc 1993 68 12 1203-1204 (Pubitemid 23351070)
43. Malik S W., Myers J L., DeRemee R A., Specks U. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med 1996 154 6 Pt 1 1851-1856 (Pubitemid 26424960)
44. Cupps T R., Silverman G J., Fauci A S. Herpes zoster in patients with treated Wegener's granulomatosis: a possible role for cyclophosphamide. Am J Med 1980 69 6 881-885 (Pubitemid 11199859)
45. Huynh-Do U, Gantenbein H, Binswanger U. Pneumocystis carinii pneumonia during immunosuppressive therapy for antineutrophil cytoplasmic autoantibody-positive vasculitis. Arch Intern Med 1995 155 8 872-874
46. Harper L, Savage C O. ANCA-associated renal vasculitis at the end of the twentieth centurya disease of older patients. Rheumatology (Oxford) 2005 44 4 495-501 (Pubitemid 41511141)
47. Charlier C, Henegar C, Launay O et al. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis 2009 68 5 658-663
48. Turnbull J, Harper L. Adverse effects of therapy for ANCA-associated vasculitis. Best Pract Res Clin Rheumatol 2009 23 3 391-401
49. Talar-Williams C, Hijazi Y M., Walther M M. et al. Cyclophosphamide- induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996 124 5 477-484 (Pubitemid 26070112)
50. Baker G L., Kahl L E., Zee B C., Stolzer B L., Agarwal A K., Medsger T A. Jr. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide: long-term case-control follow-up study. Am J Med 1987 83 1 1-9 (Pubitemid 18099020)
51. Pedersen-Bjergaard J, ErsbØll J, Hansen V L. et al. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med 1988 318 16 1028-1032 (Pubitemid 18095007)
52. Radis C D., Kahl L E., Baker G L. et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis: a 20-year followup study. Arthritis Rheum 1995 38 8 1120-1127
53. Travis L B., Curtis R E., Glimelius B et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995 87 7 524-530
54. Kinlen L J. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985 78 1A 44-49 (Pubitemid 15167365)
55. Baltus J A., Boersma J W., Hartman A P., Vandenbroucke J P. The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. Ann Rheum Dis 1983 42 4 368-373 (Pubitemid 13037092)
56. Schneider V, Kay S, Lee H M. Immunosuppression as a high-risk factor in the development of condyloma acuminatum and squamous neoplasia of the cervix. Acta Cytol 1983 27 3 220-224 (Pubitemid 13071766)
57. Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer 2002 100 1 82-85 (Pubitemid 34602069)
58. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998 57 11 682-686 (Pubitemid 28558973)
59. Stone J H., Holbrook J T., Marriott M A. et al, Wegener's Granulomatosis Etanercept Trial Research Group. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2006 54 5 1608-1618
60. Koyama H, Wada T, Nishizawa Y, Iwanaga T, Aoki Y. Cyclophosphamide- induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 1977 39 4 1403-1409 (Pubitemid 8108291)
61. Chapman R M., Sutcliffe S B. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease. Blood 1981 58 4 849-851 (Pubitemid 11015846)
62. Somers E C., Marder W, Christman G M., Ognenovski V, McCune W J. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 2005 52 9 2761-2767 (Pubitemid 41369104)
63. Bermas B L., Hill J A. Effects of immunosuppressive drugs during pregnancy. Arthritis Rheum 1995 38 12 1722-1732 (Pubitemid 26010272)
64. Hoorweg-Nijman J J., Delemarre-van de Waal H A., de Waal F C., Behrendt H. Cyclophosphamide-induced disturbance of gonadotropin secretion manifesting testicular damage. Acta Endocrinol (Copenh) 1992 126 2 143-148
65. Masala A, Faedda R, Alagna S et al. Use of testosterone to prevent cyclophosphamide-induced azoospermia. Ann Intern Med 1997 126 4 292-295 (Pubitemid 27078777)
66. Dow E, Schulman H, Agura E. Cyclophosphamide cardiac injury mimicking acute myocardial infarction. Bone Marrow Transplant 1993 12 2 169-172 (Pubitemid 23243422)
67. Bernatsky S, Ramsey-Goldman R, Clarke A E. Malignancies and cyclophosphamide exposure in Wegener's granulomatosis. J Rheumatol 2008 35 1 11-13
68. Israel H L., Patchefsky A S., Saldana M J. Wegener's granulomatosis, lymphomatoid granulomatosis, and benign lymphocytic angiitis and granulomatosis of lung: recognition and treatment. Ann Intern Med 1977 87 6 691-699 (Pubitemid 8262904)
69. Weiner S R., Paulus H E. Treatment of Wegener's granulomatosis. Semin Respir Med 1989 10 156-161
70. Weinblatt M E. Methotrexate for chronic diseases in adults. N Engl J Med 1995 332 5 330-331
71. De Groot K, Rasmussen N, Bacon P A. et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005 52 8 2461-2469 (Pubitemid 41117433)
72. Langford C A., Talar-Williams C, Sneller M C. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis: long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 2000 43 8 1836-1840
73. Langford C A., Sneller M C., Hoffman G S. Methotrexate use in systemic vasculitis. Rheum Dis Clin North Am 1997 23 4 841-853 (Pubitemid 27490245)
74. de Groot K, Mühler M, Reinhold-Keller E, Paulsen J, Gross W L. Induction of remission in Wegener's granulomatosis with low dose methotrexate. J Rheumatol 1998 25 3 492-495 (Pubitemid 28109351)
75. Langford C A., Talar-Williams C, Barron K S., Sneller M C. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999 42 12 2666-2673 (Pubitemid 30327189)
76. Cronstein B N. Molecular mechanism of methotrexate action in inflammation. Inflammation 1992 16 5 411-423
77. de Groot K, Reinhold-Keller E, Tatsis E et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis: methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum 1996 39 12 2052-2061
78. Kinder A J., Hassell A B., Brand J, Brownfield A, Grove M, Shadforth M F. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology (Oxford) 2005 44 1 61-66 (Pubitemid 40124333)
79. van Ede A E., Laan R F., Rood M J. et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001 44 7 1515-1524 (Pubitemid 32651731)
80. Morgan S L., Baggott J E., Vaughn W H. et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial. Ann Intern Med 1994 121 11 833-841
81. MacKinnon S K., Starkebaum G, Willkens R F. Pancytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1985 15 2 119-126 (Pubitemid 16215430)
82. Thomas D R., Dover J S., Camp R D. Pancytopenia induced by the interaction between methotrexate and trimethoprim-sulfamethoxazole. J Am Acad Dermatol 1987 17 6 1055-1056
83. Whiting-O'Keefe Q E., Fye K H., Sack K D. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991 90 6 711-716
84. Van Dooren-Greebe R J., Kuijpers A L., Mulder J, De Boo T, Van de Kerkhof P C. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 1994 130 2 204-210 (Pubitemid 24204616)
85. Walker A M., Funch D, Dreyer N A. et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum 1993 36 3 329-335 (Pubitemid 23090599)
86. Bergquist S R., Felson D T., Prashker M J., Freedberg K A. The cost-effectiveness of liver biopsy in rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1995 38 3 326-333
87. Kremer J M., Alarcn G S., Lightfoot R W. Jr et al, American College of Rheumatology. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994 37 3 316-328 (Pubitemid 24093622)
88. Langford C A., Talar-Williams C, Barron K S., Sneller M C. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003 114 6 463-469 (Pubitemid 36515108)
89. Zisman D A., McCune W J., Tino G, Lynch J P. III. Drug-induced pneumonitis: the role of methotrexate. Sarcoidosis Vasc Diffuse Lung Dis 2001 18 3 243-252 (Pubitemid 32896349)
90. Carroll G J., Thomas R, Phatouros C C. et al. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. J Rheumatol 1994 21 1 51-54 (Pubitemid 24044917)
91. White D A., Rankin J A., Stover D E., Gellene R A., Gupta S. Methotrexate pneumonitis: bronchoalveolar lavage findings suggest an immunologic disorder. Am Rev Respir Dis 1989 139 1 18-21 (Pubitemid 19030416)
92. Alarcn G S., Kremer J M., Macaluso M et al, Methotrexate-Lung Study Group. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis: a multicenter, case-control study. Ann Intern Med 1997 127 5 356-364 (Pubitemid 27362743)
93. Dawson J K., Graham D R., Desmond J, Fewins H E., Lynch M P. Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology (Oxford) 2002 41 3 262-267 (Pubitemid 34537861)
94. Kremer J M., Alarcn G S., Weinblatt M E. et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997 40 10 1829-1837 (Pubitemid 27452534)
95. Jones G, Mierins E, Karsh J. Methotrexate-induced asthma. Am Rev Respir Dis 1991 143 1 179-181
96. LeMense G P., Sahn S A. Opportunistic infection during treatment with low dose methotrexate. Am J Respir Crit Care Med 1994 150 1 258-260 (Pubitemid 24209969)
97. Morice A H., Lai W K. Fatal varicella zoster infection in a severe steroid dependent asthmatic patient receiving methotrexate. Thorax 1995 50 11 1221-1222
98. Moder K G., Tefferi A, Cohen M D., Menke D M., Luthra H S. Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study. Am J Med 1995 99 3 276-281
99. Nyfors A, Jensen H. Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics: a preliminary study. Dermatologica 1983 167 5 260-261 (Pubitemid 14239780)
100. Kamel O W., van de Rijn M, LeBrun D P., Weiss L M., Warnke R A., Dorfman R F. Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: frequency of Epstein-Barr virus and other features associated with immunosuppression. Hum Pathol 1994 25 7 638-643 (Pubitemid 24230740)
101. Kingsmore S F., Hall B D., Allen N B., Rice J R., Caldwell D S. Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review. J Rheumatol 1992 19 9 1462-1465
102. Shiroky J B., Frost A, Skelton J D., Haegert D G., Newkirk M M., Neville C. Complications of immunosuppression associated with weekly low dose methotrexate. J Rheumatol 1991 18 8 1172-1175
103. Hausknecht R U. Methotrexate and misoprostol to terminate early pregnancy. N Engl J Med 1995 333 9 537-540
104. Feldkamp M, Carey J C. Clinical teratology counseling and consultation case report: low dose methotrexate exposure in the early weeks of pregnancy. Teratology 1993 47 6 533-539 (Pubitemid 23172495)
105. Kozlowski R D., Steinbrunner J V., MacKenzie A H., Clough J D., Wilke W S., Segal A M. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 1990 88 6 589-592 (Pubitemid 20192270)
106. Blackburn W D. Jr, Alarcn G S. Impotence in three rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1989 32 10 1341-1342 (Pubitemid 19261088)
107. Hoffman G S. Wegener's granulomatosis: the path traveled since 1931. Medicine (Baltimore) 1994 73 6 325-329
108. Fauci A S., Haynes B F., Katz P, Wolff S M. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983 98 1 76-85 (Pubitemid 13217969)
109. Hellmich B, Lamprecht P, Gross W L. Advances in the therapy of Wegener's granulomatosis. Curr Opin Rheumatol 2006 18 1 25-32 (Pubitemid 43740402)
110. Stolk J N., Boerbooms A M., de Abreu R A. et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum 1998 41 10 1858-1866 (Pubitemid 28465541)
111. Connell W R., Kamm M A., Ritchie J K., Lennard-Jones J E. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993 34 8 1081-1085 (Pubitemid 23245359)
112. Present D H., Meltzer S J., Krumholz M P., Wolke A, Korelitz B I. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989 111 8 641-649 (Pubitemid 19259182)
113. Singh G, Fries J F., Spitz P, Williams C A. Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective. Arthritis Rheum 1989 32 7 837-843 (Pubitemid 19181005)
114. Kerstens P J., Stolk J N., De Abreu R A., Lambooy L H., van de Putte L B., Boerbooms A A. Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis. Arthritis Rheum 1995 38 1 142-145
115. Adler M, Delhaye M, Deprez C et al. Hepatic vascular disease after kidney transplantation: report of two cases and review of the literature. Nephrol Dial Transplant 1987 2 3 183-188 (Pubitemid 18004803)
116. Sterneck M, Wiesner R, Ascher N et al. Azathioprine hepatotoxicity after liver transplantation. Hepatology 1991 14 5 806-810
117. Dubinsky M C., Vasiliauskas E A., Singh H et al. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003 125 2 298-303 (Pubitemid 36929408)
118. Refabert L, Sinnassamy P, Leroy B, Fauroux B, de Blic J, Bensman A. Azathioprine-induced pulmonary haemorrhage in a child after renal transplantation. Pediatr Nephrol 1995 9 4 470-473
119. Bottomley W W., Ford G, Cunliffe W J., Cotterill J A. Aggressive squamous cell carcinomas developing in patients receiving long-term azathioprine. Br J Dermatol 1995 133 3 460-462
120. Balachandran I, Galagan K S. Cervical carcinoma in situ associated with azathioprine therapy: a case report and literature review. Acta Cytol 1984 28 6 699-702 (Pubitemid 15221898)
121. Wilkinson A H., Smith J L., Hunsicker L G. et al. Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. Transplantation 1989 47 2 293-296 (Pubitemid 19069708)
122. Silman A J., Petrie J, Hazleman B, Evans S J. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 1988 47 12 988-992 (Pubitemid 19005407)
123. Tage-Jensen U, Schlichting P, Thomsen H F., HØybye G, Thomsen A C. Malignancies following long-term azathioprine treatment in chronic liver disease: a report from the Copenhagen Study Group for Liver Diseases. Liver 1987 7 2 81-83 (Pubitemid 17112159)
124. Kinlen L J. Malignancy in autoimmune diseases. J Autoimmun 1992 5 suppl A 363-371
125. Connell W R., Kamm M A., Dickson M, Balkwill A M., Ritchie J K., Lennard-Jones J E. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994 343 8908 1249-1252 (Pubitemid 24158045)
126. Amato M P., Pracucci G, Ponziani G, Siracusa G, Fratiglioni L, Amaducci L. Long-term safety of azathioprine therapy in multiple sclerosis. Neurology 1993 43 4 831-833 (Pubitemid 23121984)
127. Westman K W., Bygren P G., Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998 9 5 842-852 (Pubitemid 28209094)
128. Voogd C E. Azathioprine, a genotoxic agent to be considered non-genotoxic in man. Mutat Res 1989 221 2 133-152 (Pubitemid 19224329)
129. Kirk E P. Organ transplantation and pregnancy: a case report and review. Am J Obstet Gynecol 1991 164 6 Pt 1 1629-1633, discussion 16331634
130. DeWitte D B., Buick M K., Cyran S E., Maisels M J. Neonatal pancytopenia and severe combined immunodeficiency associated with antenatal administration of azathioprine and prednisone. J Pediatr 1984 105 4 625-628 (Pubitemid 14003582)
131. Nowack R, Göbel U, Klooker P, Hergesell O, Andrassy K, van der Woude F J. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999 10 9 1965-1971 (Pubitemid 29402518)
132. Langford C A., Talar-Williams C, Sneller M C. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004 51 2 278-283 (Pubitemid 38468715)
133. Iatrou C, Zerbala S, Revela I et al. Mycophenolate mofetil as maintenance therapy in patients with vasculitis and renal involvement. Clin Nephrol 2009 72 1 31-37
134. Joy M S., Hogan S L., Jennette J C., Falk R J., Nachman P H. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant 2005 20 12 2725-2732 (Pubitemid 41672272)
135. Appel G B., Contreras G, Dooley M A. et al, Aspreva Lupus Management Study Group. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009 20 5 1103-1112
136. Walsh M, James M, Jayne D, Tonelli M, Manns B J., Hemmelgarn B R. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2007 2 5 968-975
137. Knight S R., Russell N K., Barcena L, Morris P J. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation 2009 87 6 785-794
138. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995 345 8961 1321-1325
139. Bove A A., Kashem A, Cross R C. et al. Factors affecting survival after heart transplantation: comparison of pre- and post-1999 listing protocols. J Heart Lung Transplant 2006 25 1 42-47 (Pubitemid 43049663)
140. Kobashigawa J A., Miller L W., Russell S D. et al, Study Investigators. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006 6 6 1377-1386 (Pubitemid 44030320)
141. Hu W, Liu C, Xie H, Chen H, Liu Z, Li L. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant 2008 23 4 1307-1312 (Pubitemid 351767500)
142. Hiemstra T F., Walsh M, Mahr A et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010 304 2381-2388
143. Allison A C., Eugui E M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000 47 2-3 85-118 (Pubitemid 30394534)
144. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004 350 10 971-980 (Pubitemid 38269274)
145. Nogueras F, Espinosa M D., Mansilla A, Torres J T., Cabrera M A., Martn-Vivaldi R. Mycophenolate mofetil-induced neutropenia in liver transplantation. Transplant Proc 2005 37 3 1509-1511 (Pubitemid 40712102)
146. Kobashigawa J A., Renlund D G., Gerosa G et al, ERL2401 Heart Study Investigators. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, Myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. J Heart Lung Transplant 2006 25 8 935-941 (Pubitemid 44143008)
147. Salvadori M, Holzer H, de Mattos A et al, ERL B301 Study Groups. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004 4 2 231-236 (Pubitemid 38248526)
148. Darji P, Vijayaraghavan R, Thiagarajan C M. et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders. Transplant Proc 2008 40 7 2262-2267
149. Oz H S., Hughes W T. Novel anti-Pneumocystis carinii effects of the
150. Husain S, Singh N. The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. Clin Infect Dis 2002 35 1 53-61 (Pubitemid 34666860)
151. Kaczmarek I, Bigdeli A K., Vogeser M et al. Defining algorithms for efficient therapeutic drug monitoring of mycophenolate mofetil in heart transplant recipients. Ther Drug Monit 2008 30 4 419-427
152. McCune W J. Mycophenolate mofetil for lupus nephritis. N Engl J Med 2005 353 21 2282-2284 (Pubitemid 41697293)
153. van Gelder T, Le Meur Y, Shaw L M. et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006 28 2 145-154 (Pubitemid 44314941)
154. Patel R V., Clark L N., Lebwohl M, Weinberg J M. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009 60 6 1001-1017
155. Uzel G, Orange J S., Poliak N, Marciano B E., Heller T, Holland S M. Complications of tumor necrosis factor- blockade in chronic granulomatous disease-related colitis. Clin Infect Dis 2010 51 12 1429-1434
156. Helbling D, Breitbach T H., Krause M. Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol 2002 14 12 1393-1395 (Pubitemid 36054931)
157. Lee T W., Fedorak R N. Tumor necrosis factor- monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology. Gastroenterol Clin North Am 2010 39 3 543-557
158. Wallis R S., Broder M S., Wong J Y., Hanson M E., Beenhouwer D O. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004 38 9 1261-1265 (Pubitemid 38608568)
159. Langford C A. Biologic immunomodulatory therapies in the vasculitic diseases. Semin Respir Crit Care Med 2004 25 5 595-607 (Pubitemid 39518253)
160. Taylor P C. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol 2010 10 3 308-315
161. Karampetsou M P., Liossis S N., Sfikakis P P. TNF- antagonists beyond approved indications: stories of success and prospects for the future. QJM 2010 103 12 917-928
162. Sfikakis P P. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010 11 180-210
163. Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 2001 44 12 2933-2935 (Pubitemid 34016214)
164. Tan A L., Holdsworth J, Pease C, Emery P, McGonagle D. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 2003 62 4 373-374 (Pubitemid 36363453)
165. Sfikakis P P., Theodossiadis P G., Katsiari C G., Kaklamanis P, Markomichelakis N N. Effect of infliximab on sight-threatening panuveitis in Behet's disease. Lancet 2001 358 9278 295-296 (Pubitemid 32738970)
166. Sari I, Birlik M, Gonen C et al. Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment. World J Gastroenterol 2008 14 18 2912-2914
167. Arbach O, Gross W L., Gause A. Treatment of refractory Churg-Strauss-syndrome (CSS) by TNF-alpha blockade. Immunobiology 2002 206 5 496-501 (Pubitemid 36192908)
168. White E S., Lynch J P. Pharmacological therapy for Wegener's granulomatosis. Drugs 2006 66 9 1209-1228 (Pubitemid 44050436)
169. Mukhtyar C, Luqmani R. Current state of tumour necrosis factor alpha blockade in Wegener's granulomatosis. Ann Rheum Dis 2005 64 suppl 4 iv31-iv36 (Pubitemid 41532014)
170. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005 352 4 351-361
171. Bartolucci P, Ramanoelina J, Cohen P et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002 41 10 1126-1132 (Pubitemid 35203539)
172. Booth A D., Jefferson H J., Ayliffe W, Andrews P A., Jayne D R. Safety and efficacy of TNFalpha blockade in relapsing vasculitis. Ann Rheum Dis 2002 61 6 559 (Pubitemid 34539105)
173. Booth A, Harper L, Hammad T et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004 15 3 717-721 (Pubitemid 38294802)
174. Lamprecht P, Voswinkel J, Lilienthal T et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002 41 11 1303-1307 (Pubitemid 35363806)
175. Hermann J, Reittner P, Scarpatetti M, Graninger W. Successful treatment of meningeal involvement in Wegener's granulomatosis with infliximab. Ann Rheum Dis 2006 65 5 691-692
176. Seror R, Mahr A, Ramanoelina J, Pagnoux C, Cohen P, Guillevin L. Central nervous system involvement in Wegener granulomatosis. Medicine (Baltimore) 2006 85 1 54-65 (Pubitemid 43884288)
177. Cheung C M., Murray P I., Savage C O. Successful treatment of Wegener's granulomatosis associated scleritis with rituximab. Br J Ophthalmol 2005 89 11 1542 (Pubitemid 41527407)
178. Dixon W G., Symmons D P., Lunt M, Watson K D., Hyrich K L., Silman A J., British Society for Rheumatology Biologics Register Control Centre Consortium British Society for Rheumatology Biologics Register. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007 56 9 2896-2904 (Pubitemid 47502735)
179. Bongartz T, Sutton A J., Sweeting M J., Buchan I, Matteson E L., Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006 295 19 2275-2285 (Pubitemid 43736578)
180. Dixon W G., Watson K D., Lunt M, Mercer L K., Hyrich K L., Symmons D P., British Society For Rheumatology Biologics Register Control Centre Consortium British Society for Rheumatology Biologics Register. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) 2010 62 6 755-763
181. Ramos-Casals M, Brito-Zern P, Muoz S et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007 86 4 242-251 (Pubitemid 47067483)
182. Dixon W G., Hyrich K L., Watson K D., Lunt M, Symmons D P., BSRBR Control Centre Consortium British Society for Rheumatology Biologics Register. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2010 69 6 1086-1091
183. Utz J P., Limper A H., Kalra S et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003 124 1 177-185 (Pubitemid 36851350)
184. Baughman R P., Drent M, Kavuru M et al, Sarcoidosis Investigators. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006 174 7 795-802 (Pubitemid 44511661)
185. Khanna D, Liebling M R., Louie J S. Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol 2003 30 8 1864-1867 (Pubitemid 36962468)
186. Doty J D., Mazur J E., Judson M A. Treatment of sarcoidosis with infliximab. Chest 2005 127 3 1064-1071 (Pubitemid 40775543)
187. Baughman R P., Lower E E. Novel therapies for sarcoidosis. Semin Respir Crit Care Med 2007 28 1 128-133 (Pubitemid 46364277)
188. Panselinas E, Rodgers J K., Judson M A. Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respirology 2009 14 4 522-528
189. Raghu G, Brown K K., Costabel U et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008 178 9 948-955
190. Bargagli E, Galeazzi M, Rottoli P. Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis. Eur Respir J 2004 24 4 708 (Pubitemid 39406147)
191. Antoniou K M., Mamoulaki M, Malagari K et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol 2007 25 1 23-28 (Pubitemid 46477481)
192. Ostör A J., Chilvers E R., Somerville M F. et al. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. J Rheumatol 2006 33 3 622-628 (Pubitemid 43334590)
193. Kramer N, Chuzhin Y, Kaufman L D., Ritter J M., Rosenstein E D. Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum 2002 47 6 670-671 (Pubitemid 35461322)
194. Lindsay K, Melsom R, Jacob B K., Mestry N. Acute progression of interstitial lung disease: a complication of etanercept particularly in the presence of rheumatoid lung and methotrexate treatment. Rheumatology (Oxford) 2006 45 8 1048-1049 (Pubitemid 44283069)
195. Huggett M T., Armstrong R. Adalimumab-associated pulmonary fibrosis. Rheumatology (Oxford) 2006 45 10 1312-1313
196. Schoe A, van der Laan-Baalbergen N E., Huizinga T W., Breedveld F C., van Laar J M. Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab. Arthritis Rheum 2006 55 1 157-159 (Pubitemid 43235143)
197. Curtis J R., Patkar N, Xie A et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007 56 4 1125-1133 (Pubitemid 46608637)
198. Keane J, Gershon S, Wise R P. et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001 345 15 1098-1104
199. Strangfeld A, Listing J, Herzer P et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009 301 7 737-744
200. Esteve M, Saro C, Gonzlez-Huix F, Suarez F, Forn M, Viver J M. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004 53 9 1363-1365 (Pubitemid 39120128)
201. Kaur N, Mahl T C. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 2007 52 6 1481-1484 (Pubitemid 46776482)
202. Warris A, BjØrneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001 344 14 1099-1100 (Pubitemid 32267986)
203. De Rosa F G., Shaz D, Campagna A C., Dellaripa P E., Khettry U, Craven D E. Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case? Infect Control Hosp Epidemiol 2003 24 7 477-482 (Pubitemid 36919265)
204. True D G., Penmetcha M, Peckham S J. Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab. J Rheumatol 2002 29 7 1561-1563 (Pubitemid 34755630)
205. Galandiuk S, Davis B R. Infliximab-induced disseminated histoplasmosis in a patient with Crohn's disease. Nat Clin Pract Gastroenterol Hepatol 2008 5 5 283-287 (Pubitemid 351637914)
206. Williams G, Khan A A., Schweiger F. Listeria meningitis complicating infliximab treatment for Crohn's disease. Can J Infect Dis Med Microbiol 2005 16 5 289-292 (Pubitemid 41719722)
207. Martin-Mola E, Balsa A. Infectious complications of biologic agents. Rheum Dis Clin North Am 2009 35 1 183-199
208. Vassilopoulos D, Apostolopoulou A, Hadziyannis E et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2010 69 7 1352-1355
209. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007 56 5 1433-1439 (Pubitemid 46764070)
210. Askling J, Bongartz T. Malignancy and biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008 20 3 334-339 (Pubitemid 351483325)
211. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007 56 9 2886-2895 (Pubitemid 47502734)
212. Lakatos P L., Miheller P. Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD? Curr Drug Targets 2010 11 2 179-186
213. Mariette X. Lymphoma, rheumatoid arthritis, and TNFalpha antagonists. Joint Bone Spine 2010 77 3 195-197
214. Brown S L., Greene M H., Gershon S K., Edwards E T., Braun M M. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002 46 12 3151-3158 (Pubitemid 35453523)
215. Dixon W G., Symmons D P. What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. Ann Rheum Dis 2007 66 9 1132-1136 (Pubitemid 47309726)
216. Atzeni F, Turiel M, Caporali R et al. The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. Autoimmun Rev 2010 9 12 835-839
217. Sidiropoulos P I., Siakka P, Pagonidis K et al. Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients. Scand J Rheumatol 2009 38 1 6-10
218. Dixon W G., Watson K D., Lunt M, Hyrich K L., Silman A J., Symmons D P., British Society for Rheumatology Biologics Register Control Centre Consortium British Society for Rheumatology Biologics Register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007 56 9 2905-2912 (Pubitemid 47502736)
219. Anker S D., Coats A J. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002 86 2-3 123-130 (Pubitemid 35284800)
220. Chung E S., Packer M, Lo K H., Fasanmade A A., Willerson J T., Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003 107 25 3133-3140 (Pubitemid 36793081)
221. Mohan N, Edwards E T., Cupps T R. et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001 44 12 2862-2869 (Pubitemid 34016206)
222. Chung J H., Van Stavern G P., Frohman L P., Turbin R E. Adalimumab-associated optic neuritis. J Neurol Sci 2006 244 1-2 133-136
223. Enayati P J., Papadakis K A. Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. J Clin Gastroenterol 2005 39 4 303-306 (Pubitemid 40393245)
224. Bensouda-Grimaldi L, Mulleman D, Valat J P., Autret-Leca E. Adalimumab-associated multiple sclerosis. J Rheumatol 2007 34 1 239-240, discussion 240
225. Bechtel M, Sanders C, Bechtel A. Neurological complications of biologic therapy in psoriasis: a review. J Clin Aesthet Dermatol 2009 2 11 27-32
226. Yamamoto M, Takahashi H, Wakasugi H et al. Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis. Mod Rheumatol 2007 17 1 72-74 (Pubitemid 46758774)
227. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004 126 6 1593-1610 (Pubitemid 38649876)
228. Costa M F., Said N R., Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008 37 6 381-387 (Pubitemid 351734520)
229. Mohan N, Edwards E T., Cupps T R. et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 2004 31 10 1955-1958 (Pubitemid 39336719)
230. Stasi R, Stipa E, Del Poeta G, Amadori S, Newland A C., Provan D. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 2006 45 11 1432-1436 (Pubitemid 44605482)
231. Aries P M., Hellmich B, Voswinkel J et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006 65 7 853-858
232. Keogh K A., Wylam M E., Stone J H., Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005 52 1 262-268 (Pubitemid 40129256)
233. Memet B, Rudinskaya A, Krebs T, Oelberg D. Wegener granulomatosis with massive intracerebral hemorrhage: remission of disease in response to rituximab. J Clin Rheumatol 2005 11 6 314-318 (Pubitemid 44384022)
234. Tamura N, Matsudaira R, Hirashima M et al. Two cases of refractory Wegener's granulomatosis successfully treated with rituximab. Intern Med 2007 46 7 409-414 (Pubitemid 46585484)
235. Specks U, Fervenza F C., McDonald T J., Hogan M C. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001 44 12 2836-2840 (Pubitemid 34016203)
236. Omdal R, Wildhagen K, Hansen T, Gunnarsson R, Kristoffersen G. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol 2005 34 3 229-232 (Pubitemid 40978644)
237. Brihaye B, Aouba A, Pagnoux C, Cohen P, Lacassin F, Guillevin L. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. Clin Exp Rheumatol 2007 25 1, suppl 44 S23-S27 (Pubitemid 46656590)
238. Hermle T, Goestemeyer A K., Sweny P, Burns A. Successful therapeutic use of rituximab in refractory Wegener's granulomatosis after renal transplantation. Clin Nephrol 2007 68 5 322-326 (Pubitemid 350047766)
239. Roccatello D, Baldovino S, Alpa M et al. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol 2008 26 3, suppl 49 S67-S71
240. Sharma A, Kumar S, Wanchu A et al. Successful treatment of hypertrophic pachymeningitis in refractory Wegener's granulomatosis with rituximab. Clin Rheumatol 2010 29 1 107-110
241. Taylor S R., Salama A D., Joshi L, Pusey C D., Lightman S L. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 2009 60 5 1540-1547
242. Jones R B., Ferraro A J., Chaudhry A N. et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009 60 7 2156-2168
243. Martinez Del Pero M, Chaudhry A, Jones R B., Sivasothy P, Jani P, Jayne D. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Clin Otolaryngol 2009 34 4 328-335
244. Avivi I, Robinson S, Goldstone A. Clinical use of rituximab in haematological malignancies. Br J Cancer 2003 89 8 1389-1394 (Pubitemid 37390853)
245. McLaughlin P, Grillo-Lpez A J., Link B K. et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998 16 8 2825-2833 (Pubitemid 28363048)
246. Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005 105 4 1417-1423 (Pubitemid 40223656)
247. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002 346 4 235-242 (Pubitemid 34438862)
248. Selewski D T., Shah G V., Mody R J., Rajdev P A., Mukherji S K. Rituximab (Rituxan). AJNR Am J Neuroradiol 2010 31 7 1178-1180
249. Gürcan H M., Keskin D B., Stern J N., Nitzberg M A., Shekhani H, Ahmed A R. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 2009 9 1 10-25
250. Hauser S L., Waubant E, Arnold D L. et al, HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008 358 7 676-688 (Pubitemid 351240747)
251. Reff M E., Carner K, Chambers K S. et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994 83 2 435-445 (Pubitemid 24030569)
252. Pescovitz M D. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006 6 5 Pt 1 859-866 (Pubitemid 44356635)
253. Falk R J., Jennette J C. Rituximab in ANCA-associated disease. N Engl J Med 2010 363 3 285-286
254. Ng C M., Bruno R, Combs D, Davies B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 2005 45 7 792-801 (Pubitemid 40875331)
255. Adeli M M., Eichner B H., Thornburg C, Williams L. Persistent antibody depletion after rituximab in three children with autoimmune cytopenias. Pediatr Hematol Oncol 2009 26 8 566-572
256. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001 358 9292 1511-1513 (Pubitemid 33055705)
257. Carson K R., Evens A M., Richey E A. et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009 113 20 4834-4840
258. Goldberg S L., Pecora A L., Alter R S. et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002 99 4 1486-1488 (Pubitemid 34547110)
259. Shelton E, Yong M, Cohney S. Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection. Nephrology (Carlton) 2009 14 7 696-699
260. Cohen S B., Emery P, Greenwald M W. et al, REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006 54 9 2793-2806 (Pubitemid 44497758)
261. van Vollenhoven R F., Emery P, Bingham C O. III et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010 37 3 558-567
262. Sfikakis P P., Boletis J N., Lionaki S et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005 52 2 501-513 (Pubitemid 40216314)
263. Lim S H., Esler W V., Zhang Y et al. B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period. Leuk Lymphoma 2008 49 1 152-153 (Pubitemid 351146895)
264. Cattaneo C, Spedini P, Casari S et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 2006 47 6 1013-1017 (Pubitemid 44102962)
265. Aksoy S, Harputluoglu H, Kilickap S et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007 48 7 1307-1312 (Pubitemid 47079357)
266. Aksoy S, Dizdar O, Hayran M, Harputluolu H. Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis. Leuk Lymphoma 2009 50 3 357-365
267. Furst D E., Keystone E C., Kirkham B et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008 67 suppl 3 iii2-iii25 (erratum in Ann Rheum Dis 2009;68(3):452, Kavanaugh A [added])
268. Rafailidis P I., Kakisi O K., Vardakas K, Falagas M E. Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer 2007 109 11 2182-2189 (Pubitemid 46805005)
269. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005 31 6 456-473
270. Genovese M C., Breedveld F C., Emery P et al. Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients. Ann Rheum Dis 2009 68 12 1894-1897
271. Lutt J R., Pisculli M L., Weinblatt M E., Deodhar A, Winthrop K L. Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis. J Rheumatol 2008 35 8 1683-1685
272. Ozgönenel B, Moonka D, Savaan S. Fulminant hepatitis B following rituximab therapy in a patient with Evans syndrome and large B-cell lymphoma. Am J Hematol 2006 81 4 302
273. Tsutsumi Y, Tanaka J, Kawamura T et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 2004 83 1 58-60 (Pubitemid 38088239)
274. Yang S H., Kuo S H. Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma. Ann Hematol 2008 87 4 325-327
275. Wang F, Xu R H., Luo H Y. et al. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer 2008 8 115
276. Lok A S. Navigating the maze of hepatitis B treatments. Gastroenterology 2007 132 4 1586-1594 (Pubitemid 46627589)
277. Fukushima N, Mizuta T, Tanaka M et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 2009 20 12 2013-2017
278. Fabrizi F, Martin P, Elli A et al. Hepatitis C virus infection and rituximab therapy after renal transplantation. Int J Artif Organs 2007 30 5 445-449 (Pubitemid 47072702)
279. Ennishi D, Terui Y, Yokoyama M et al. Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. Am J Hematol 2008 83 1 59-62
280. Garca-Surez J, de Miguel D, Krsnik I, Baas H, Arribas I, Burgaleta C. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol 2005 80 4 271-281 (Pubitemid 41746174)
281. Brooks B R., Walker D L. Progressive multifocal leukoencephalopathy. Neurol Clin 1984 2 2 299-313
282. Marzocchetti A, Wuthrich C, Tan C S. et al. Rearrangement of the JC virus regulatory region sequence in the bone marrow of a patient with rheumatoid arthritis and progressive multifocal leukoencephalopathy. J Neurovirol 2008 14 5 455-458 (Pubitemid 352762885)
283. Molloy E S., Calabrese L H. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev 2008 8 2 144-146
284. Ward M M., Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum 1999 42 4 780-789 (Pubitemid 29172000)
285. Hugle B, Solomon M, Harvey E et al. Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener's granulomatosis. Arthritis Care Res (Hoboken) 2010 62 11 1661-1664
286. Motto D G., Williams J A., Boxer L A. Rituximab for refractory childhood autoimmune hemolytic anemia. Isr Med Assoc J 2002 4 11 1006-1008
287. Mukhtyar C, Guillevin L, Cid M C. et al, European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009 68 3 310-317
288. Teichmann L L., Woenckhaus M, Vogel C, Salzberger B, Schölmerich J, Fleck M. Fatal pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. Rheumatology (Oxford) 2008 47 8 1256-1257 (Pubitemid 352038242)
289. Alexandrescu D T., Dutcher J P., O'Boyle K, Albulak M, Oiseth S, Wiernik P H. Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma. Leuk Lymphoma 2004 45 11 2321-2325 (Pubitemid 39504329)
290. Hainsworth J D., Litchy S, Lamb M R., Rodriguez G I., Scroggin C Jr, Greco F A. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial. Clin Lymphoma 2003 4 1 36-42 (Pubitemid 36826875)
291. Heresi G A., Farver C F., Stoller J K. Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature. Respiration 2008 76 4 449-453
292. Leon R J., Gonsalvo A, Salas R, Hidalgo N C. Rituximab-induced acute pulmonary fibrosis. Mayo Clin Proc 2004 79 7 949-953, 953
293. Schlesinger C, Koss M N. The organizing pneumonias: an update and review. Curr Opin Pulm Med 2005 11 5 422-430 (Pubitemid 41291087)
294. Wagner S A., Mehta A C., Laber D A. Rituximab-induced interstitial lung disease. Am J Hematol 2007 82 10 916-919 (Pubitemid 47502698)
295. Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol 2003 121 6 913-918 (Pubitemid 36760311)
296. Yi J H., Kim S J., Ahn H K., Lee S J., Chang M H., Kim W S. Rituximab-induced acute thrombocytopenia: a case report and review of the literature. Med Oncol 2009 26 1 45-48
297. Klink D T., van Elburg R M., Schreurs M W., van Well G T. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol 2008 2008 271363
298. Ojeda-Uribe M, Gilliot C, Jung G, Drenou B, Brunot A. Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. J Perinatol 2006 26 4 252-255
299. Østensen M, Lockshin M, Doria A et al. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford) 2008 47 suppl 3 iii28-iii31
300. Kazatchkine M D., Kaveri S V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001 345 10 747-755
301. Ito-Ihara T, Ono T, Nogaki F et al. Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis. Nephron Clin Pract 2006 102 1 c35-c42 (Pubitemid 43250931)
302. Jayne D R., Chapel H, Adu D et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000
303. Chung S A., Seo P. Advances in the use of biologic agents for the treatment of systemic vasculitis. Curr Opin Rheumatol 2009 21 1 3-9
304. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005 29 3 173-184 (Pubitemid 43041668)